U.S. Markets close in 2 hrs 12 mins

Oncternal Therapeutics, Inc. (ONCT)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
5.36+0.38 (+7.63%)
As of 1:48PM EDT. Market open.

Oncternal Therapeutics, Inc.

12230 El Camino Real
Suite 300
San Diego, CA 92130
United States
858 434 1113
http://www.oncternal.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees12

Key Executives

NameTitlePayExercisedYear Born
Dr. James B. BreitmeyerPres, CEO & Director781.8kN/A1954
Dr. Gunnar F. Kaufmann Ph.D.Chief Scientific Officer525.89kN/A1976
Mr. Richard G. VincentCFO, Treasurer & Sec.N/AN/A1964
Dr. Rajesh Krishnan Ph.D.Chief Technology OfficerN/AN/AN/A
Mr. Chase C. LeavittGen. CounselN/AN/A1982
Dr. Edwina Baskin-BeyActing Chief Medical OfficerN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical need. Its pipeline includes cirmtuzumab, an investigational monoclonal antibody that is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of patients with B-cell lymphoid malignancies, including mantle cell lymphoma and chronic lymphocytic leukemia. The company also develops a chimeric antigen receptor T cell therapy that targets Receptor tyrosine kinase-like Orphan Receptor 1, which is in preclinical development as a potential treatment for hematologic cancers and solid tumors. In addition, it is developing TK216, an investigational small molecule that inhibits the E26 Transformation Specific family of oncoproteins. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; Shanghai Pharmaceutical (USA) Inc.; Selexis S.A.; and University of Tennessee Research Foundation. The company is headquartered in San Diego, California.

Corporate Governance

Oncternal Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.